Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics, Inc. Chief Medical Officer Tiffany Eul Davis Inglis sold 8,024 shares of Class A Common Stock on October 12, 2026, at a weighted average price of $2.03 per share. The shares were sold in a block trade at prices ranging from $2.03 to $2.05 to cover tax withholding obligations connected with vesting restricted stock units. The issuer mandated the sell-to-cover transaction, which was not discretionary. She directly held 83,565 shares after the sale.
Sera Prognostics, Inc. officer Tiffany Inglis reported a sale of 8,024 Class A common shares associated with restricted stock unit vesting on October 12, 2026. The remarks state that the issuer required sell-to-cover transactions to fund tax withholding and that the sale was not discretionary. The notice lists an aggregate market value of $16,294 for the shares.
SERA PROGNOSTICS, INC. (SERA) reported that Chief Commercial Officer Dyaarl Lee Anderson Jr. sold 1,800 shares of Class A Common Stock on September 10, 2026 at a weighted average price of about $2.00 per share. The company states the shares were sold to cover tax withholding on vesting RSUs under a mandatory “sell to cover” arrangement and are not a discretionary sale. Following this transaction, he directly holds 76,198 shares of Class A Common Stock.
SERA PROGNOSTICS, INC. (SERA) reported that Chief Executive Officer and director Zhenya Lindgardt sold 7,022 shares of Class A Common Stock on September 10, 2026 at a weighted average price of about $2.00 per share. The sale was made to cover tax withholding on vesting RSUs under a mandated “sell to cover” arrangement and is described as not a discretionary transaction. After this sale, Lindgardt directly holds 837,848 shares of Class A Common Stock.
SERA PROGNOSTICS, INC. (SERA) reported that Chief Medical Officer Tiffany Eul Davis Inglis sold 486 shares of Class A Common Stock on September 10, 2026 at a weighted average price of about $2.00 per share. The sale was made solely to cover tax withholding on vesting RSUs and was mandated by the company’s sell-to-cover policy, leaving her with 91,589 directly held shares.
SERA PROGNOSTICS, INC. (SERA) reported that its General Counsel, Benjamin Jackson, sold 2,190 shares of Class A Common Stock on September 10, 2026 at a weighted average price of about $2.00 per share. The shares were sold to cover tax withholding on vested RSUs under a mandated "sell to cover" arrangement. After this transaction, he held 159,566 shares directly.
SERA PROGNOSTICS, INC. (SERA) is the issuer for which Zhenya Lindgardt filed a Rule 144 notice covering the planned sale of 7,022 shares of Class A Common Stock on September 10, 2026. The shares relate to vested restricted stock units, with sales used to satisfy tax withholding obligations.
The company required these tax obligations to be funded via sell-to-cover transactions, so the sales are described as non-discretionary for the reporting person. Over the prior three months, Lindgardt reported additional sales of 6,990 shares on June 11, 2026 and 20,139 shares on September 8, 2026 under Rule 144.
Sera Prognostics, Inc. (SERA) is the issuer for which officer Tiffany Inglis has filed a Form 144 notice to sell 486 shares of Class A Common Stock through Morgan Stanley Smith Barney LLC on or about September 10, 2026. The filing states the sale is to cover tax withholding obligations from restricted stock unit vesting and is mandated by the issuer’s election, rather than being a discretionary transaction by the reporting person. During the prior three months, Inglis previously sold 362 shares of Class A Common Stock.
SERA PROGNOSTICS, INC. (SERA) reports that officer Benjamin G. Jackson filed a notice to sell Class A common stock under Rule 144. The planned sale involves 2,190 shares on September 10, 2026, in connection with the vesting of restricted stock units and is executed through Morgan Stanley Smith Barney LLC on NASDAQ.
The company states the transaction is a mandatory "sell to cover" to satisfy tax withholding obligations from RSU vesting and is not a discretionary trade by Jackson. During the prior three months, Jackson sold 2,179 shares of Class A common stock on June 11, 2026.
SERA PROGNOSTICS, INC. (SERA) received a Rule 144 notice that officer Austin Aerts plans to sell 1,509 shares of Class A common stock through Morgan Stanley Smith Barney LLC on or about September 10, 2026, in connection with restricted stock unit vesting. The company disclosure states the sale is to cover tax withholding obligations under an issuer-mandated sell-to-cover arrangement and is not a discretionary transaction by Aerts. Additional sales in the prior three months included 2,037 and 13,591 shares of Class A common stock on June 11, 2026 and September 8, 2026, respectively.